Physician profile
Jeff Eggart
NPI 1295798767
$1,768.11
in general payments reported to CMS, 2019-2025
15 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $184 · 2021: $309 · 2022: $339 · 2023: $191 · 2024: $143 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $537.95 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $189.45 | 2021-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $172.27 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.68 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $138.40 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $127.26 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $107.55 | 2022-2025 | |
| Abbott Laboratories | $103.66 | 2021-2022 | |
| Amarin Pharma, INC. | $87.57 | 2019 | |
| Merck Sharp & Dohme LLC | $72.29 | 2021-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $24.27 | 2019 | |
| Novo Nordisk INC | $21.99 | 2024 | Ozempic, Rybelsus |
| Currax Pharmaceuticals LLC | $13.20 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| G Medical Diagnostic Services, INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Eggart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.